Kura Oncology (NASDAQ:KURA) Downgraded by StockNews.com to “Hold”

Kura Oncology (NASDAQ:KURA) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

Other equities analysts also recently issued reports about the company. Scotiabank reduced their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. Wedbush reaffirmed an “outperform” rating and set a $36.00 target price on shares of Kura Oncology in a research report on Tuesday, April 8th. UBS Group lowered their price target on Kura Oncology from $27.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, March 6th. BTIG Research downgraded shares of Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. Finally, Cantor Fitzgerald upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Kura Oncology has an average rating of “Moderate Buy” and an average target price of $23.89.

Kura Oncology Stock Down 0.3 %

NASDAQ:KURA opened at $6.47 on Friday. The company has a 50-day moving average of $6.73 and a 200 day moving average of $9.58. Kura Oncology has a 1-year low of $5.41 and a 1-year high of $23.48. The firm has a market cap of $522.63 million, a PE ratio of -2.74 and a beta of 0.50. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.15). The company had revenue of $14.11 million during the quarter, compared to the consensus estimate of $39.08 million. As a group, research analysts anticipate that Kura Oncology will post -2.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtus ETF Advisers LLC grew its position in Kura Oncology by 71.6% during the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company’s stock worth $64,000 after purchasing an additional 3,061 shares during the period. Harbor Advisors LLC purchased a new stake in shares of Kura Oncology in the fourth quarter worth about $87,000. Pallas Capital Advisors LLC acquired a new stake in Kura Oncology during the first quarter worth about $66,000. E Fund Management Co. Ltd. purchased a new position in Kura Oncology during the fourth quarter valued at approximately $90,000. Finally, Corton Capital Inc. acquired a new position in Kura Oncology in the fourth quarter valued at approximately $99,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.